Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.

Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion

Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature

Supriya Lifescience reports 19% revenue increase in Q2 FY25

The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24

GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr

The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market

Mankind Pharma completes acquisition of BSV

Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.

Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC

Lupin appoints Claus Jepsen as President, Global Specialty

KIMS signs MoU with Wipro GE Healthcare valuing upto Rs. 700 Cr

Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets

Granules now has a total of 67 ANDA approvals from the USFDA